Skip to content

Study · Randomized controlled trial · n = 218 · 2015

4 results

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR and 12 more

Show all authors

Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS

The New England journal of medicine1 Mar 2015Cited by 368 (Europe PMC)

PMID25738668 (opens in a new tab)PMCIDPMC4405231 (opens in a new tab)DOI10.1056/nejmoa1413204 (opens in a new tab)PepBankPUB-25738668
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with breast cancer, ovarian failure occurred in 8% with goserelin plus chemotherapy versus 22% with chemotherapy alone.

    In plain wordsIn women with breast cancer, ovarian failure was less common with added goserelin than chemotherapy alone.

    Peptide
    Goserelin
    Outcome
    DecreaseOvarian failure at 2 years
    Study

    n = 135

    Comparator
    Chemotherapy alone
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Ovarian failure
    8%
    Goserelin
    Ovarian failure
    22%
    Chemotherapy alone
    Odds ratio
    0.3
    95% CI 0.09 to 0.97

    Source sentences

    Summary
    Among 135 with complete primary end-point data, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group (odds ratio, 0.30; 95% confidence interval [CI], 0.09 to 0.97; two-sided P=0.04).
    1 context sentence
    Summary · context
    We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with breast cancer, pregnancy occurred in 21% with goserelin plus chemotherapy versus 11% with chemotherapy alone (P=0.03).

    In plain wordsIn women with breast cancer, pregnancy was more common with added goserelin than chemotherapy alone.

    Peptide
    Goserelin
    Outcome
    IncreasePregnancy
    Study

    n = 218

    Comparator
    Chemotherapy alone
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Pregnancy
    21%
    Goserelin plus chemotherapy
    Pregnancy
    11%
    Chemotherapy alone

    Source sentences

    Summary
    Among the 218 patients who could be evaluated, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21% vs. 11%, P=0.03); women in the goserelin group also had improved disease-free survival (P=0.04) and overall survival (P=0.05).
    1 context sentence
    Summary · context
    We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with breast cancer, added goserelin improved disease-free survival versus chemotherapy alone (P=0.04).

    In plain wordsIn women with breast cancer, added goserelin improved disease-free survival compared with chemotherapy alone.

    Peptide
    Goserelin
    Outcome
    IncreaseDisease-free survival
    Study

    n = 218

    Comparator
    Chemotherapy alone
    Analysis
    Secondary
    Outcome group
    Cancer progression · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among the 218 patients who could be evaluated, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21% vs. 11%, P=0.03); women in the goserelin group also had improved disease-free survival (P=0.04) and overall survival (P=0.05).
    1 context sentence
    Summary · context
    We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with breast cancer, added goserelin improved overall survival versus chemotherapy alone (P=0.05).

    In plain wordsIn women with breast cancer, added goserelin improved overall survival compared with chemotherapy alone.

    Peptide
    Goserelin
    Outcome
    IncreaseOverall survival
    Study

    n = 218

    Comparator
    Chemotherapy alone
    Analysis
    Secondary
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among the 218 patients who could be evaluated, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21% vs. 11%, P=0.03); women in the goserelin group also had improved disease-free survival (P=0.04) and overall survival (P=0.05).
    1 context sentence
    Summary · context
    We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 1 ongoing · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT06225284

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients

National Taiwan University Hospitaln = 12422 Aug 2024 to est. Dec 2030

Triple Negative Breast Cancer · Premenopausal Breast Cancer

Trial pageClinicalTrials.govUpdated 29 Apr 2025
CompletedPhase 3Results postedNCT02518191

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Xiangyun Zongn = 3451 Sept 2015 to 12 Jan 2021

Breast Cancer

Trial pageClinicalTrials.govUpdated 11 Jun 2021
CompletedPhase 3Results postedNCT00068601

S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

SWOG Cancer Research Networkn = 257Oct 2003 to Sept 2016

Breast Cancer · Infertility · Menopausal Symptoms

Trial pageClinicalTrials.govUpdated 30 Dec 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.